UCB's stock slides despite Bimzelx revenue beating forecasts
UCB's shares dropped Thursday on investor concern that the Belgian pharma could be overpromising on its full-year forecast, even as sales of its lead drug topped analysts' expectations. The company reported Bimzelx, which is used ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.